Details for New Drug Application (NDA): 022059
✉ Email this page to a colleague
The generic ingredient in TYKERB is lapatinib ditosylate. There are seven drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the lapatinib ditosylate profile page.
Summary for 022059
Tradename: | TYKERB |
Applicant: | Novartis |
Ingredient: | lapatinib ditosylate |
Patents: | 1 |
Pharmacology for NDA: 022059
Mechanism of Action | Protein Kinase Inhibitors |
Suppliers and Packaging for NDA: 022059
Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
---|---|---|---|---|---|---|---|---|
TYKERB | lapatinib ditosylate | TABLET;ORAL | 022059 | NDA | Novartis Pharmaceuticals Corporation | 0078-0671 | 0078-0671-19 | 150 TABLET in 1 BOTTLE (0078-0671-19) |
Profile for product number 001
Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | EQ 250MG BASE | ||||
Approval Date: | Mar 13, 2007 | TE: | AB | RLD: | Yes | ||||
Patent: | 8,821,927 | Patent Expiration: | Sep 18, 2029 | Product Flag? | Y | Substance Flag? | Y | Delist Request? |
Expired US Patents for NDA 022059
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Novartis | TYKERB | lapatinib ditosylate | TABLET;ORAL | 022059-001 | Mar 13, 2007 | 7,157,466 | ⤷ Subscribe |
Novartis | TYKERB | lapatinib ditosylate | TABLET;ORAL | 022059-001 | Mar 13, 2007 | 6,391,874 | ⤷ Subscribe |
Novartis | TYKERB | lapatinib ditosylate | TABLET;ORAL | 022059-001 | Mar 13, 2007 | 8,513,262 | ⤷ Subscribe |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription